XTX Topco Ltd Makes New Investment in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

XTX Topco Ltd purchased a new position in shares of Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm purchased 80,423 shares of the biopharmaceutical company’s stock, valued at approximately $126,000.

Several other institutional investors have also modified their holdings of LXRX. FMR LLC lifted its position in Lexicon Pharmaceuticals by 28.9% in the 3rd quarter. FMR LLC now owns 49,867,042 shares of the biopharmaceutical company’s stock valued at $78,291,000 after acquiring an additional 11,179,919 shares in the last quarter. Point72 Asset Management L.P. lifted its holdings in shares of Lexicon Pharmaceuticals by 605.2% in the second quarter. Point72 Asset Management L.P. now owns 4,121,191 shares of the biopharmaceutical company’s stock valued at $6,924,000 after purchasing an additional 3,536,805 shares in the last quarter. Nantahala Capital Management LLC acquired a new position in shares of Lexicon Pharmaceuticals during the second quarter worth about $3,871,000. Marshall Wace LLP grew its holdings in shares of Lexicon Pharmaceuticals by 138.5% during the second quarter. Marshall Wace LLP now owns 1,190,448 shares of the biopharmaceutical company’s stock worth $2,000,000 after buying an additional 691,276 shares in the last quarter. Finally, BBR Partners LLC raised its position in Lexicon Pharmaceuticals by 800.0% in the 2nd quarter. BBR Partners LLC now owns 270,000 shares of the biopharmaceutical company’s stock valued at $454,000 after buying an additional 240,000 shares during the last quarter. Institutional investors own 74.70% of the company’s stock.

Analyst Ratings Changes

LXRX has been the subject of a number of recent research reports. Leerink Partners set a $6.00 price target on Lexicon Pharmaceuticals and gave the stock an “outperform” rating in a research report on Friday, October 18th. Needham & Company LLC reaffirmed a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Friday, November 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $6.00 price target on shares of Lexicon Pharmaceuticals in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $6.00.

Lexicon Pharmaceuticals Trading Down 1.2 %

Shares of Lexicon Pharmaceuticals stock opened at $0.71 on Friday. The stock has a market cap of $175.99 million, a P/E ratio of -0.95 and a beta of 1.07. The company has a quick ratio of 7.43, a current ratio of 7.45 and a debt-to-equity ratio of 0.56. Lexicon Pharmaceuticals, Inc. has a 12-month low of $0.62 and a 12-month high of $3.73. The business’s 50 day moving average is $1.18 and its 200-day moving average is $1.56.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.01). Lexicon Pharmaceuticals had a negative return on equity of 107.38% and a negative net margin of 4,109.41%. The firm had revenue of $1.75 million for the quarter, compared to the consensus estimate of $3.14 million. During the same period last year, the company posted ($0.21) earnings per share. Equities research analysts predict that Lexicon Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.